Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry

CONNECT MM Registry Investigators

doi:10.1016/j.clml.2019.10.002

Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry

CONNECT MM Registry Investigators

Research output: Contribution to journal › Comment/debate

7 Scopus citations

Original language	English
Pages (from-to)	272-276
Number of pages	5
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.clml.2019.10.002
State	Published - May 2020

Keywords

Community
Real-world
Sankey
Therapies
Transitions

Access to Document

10.1016/j.clml.2019.10.002

Cite this

@article{12fea0cdd9fc46c09edfb388ae679892,

title = "Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry",

keywords = "Community, Real-world, Sankey, Therapies, Transitions",

author = "{CONNECT MM Registry Investigators} and Sundar Jagannath and Rifkin, {Robert M.} and Gasparetto, {Cristina J.} and Kathleen Toomey and Durie, {Brian G.M.} and Hardin, {James W.} and Terebelo, {Howard R.} and Lynne Wagner and Mohit Narang and Sikander Ailawadhi and Omel, {James L.} and Shankar Srinivasan and Mia He and Brian Ung and Amani Kitali and Flick, {E. Dawn} and Amit Agarwal and Rafat Abonour",

note = "Funding Information: The authors thank the patients and their families, nurses, study personnel, and investigators who participated in the Connect MM Registry. This study was funded by Celgene Corporation , which had a role in the study design, collection, analysis and interpretation of data, provided medical writing support, and was involved in the decision to submit the article for publication. Maryann Obiorah provided drafts and editorial assistance to the authors during the preparation of this manuscript, supported by funding from Celgene Corporation . All authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of the article; revised the manuscript critically for important intellectual content; approved the final version to be published; and agreed to be accountable for all aspects of the article. Funding Information: S. Jagannath has provided consultancy services to Celgene, Bristol-Myers Squibb, Novartis, and Merck; he has participated in speakers' bureaus for MMRF and Medicom. R.M. Rifkin has provided consultancy services to Amgen, Boehringer Ingelheim, Celgene, EMD Serono, Sandoz, and Takeda; he owns stock in McKesson. C.J. Gasparetto has received honoraria from Janssen, Bristol-Myers Squibb, Celgene, and Takeda and has provided consultancy services to Janssen, Bristol-Myers Squibb, and Celgene; she has received travel reimbursement from Janssen, Bristol-Myers Squibb, and Celgene, and has received research funding from Celgene. K. Toomey has provided consultancy services to Celgene, has participated in speakers' bureaus for Myriad Genetics, and has received travel reimbursement from Dava Oncology. B.G.M. Durie has provided consultancy services to Takeda and Janssen. J.W. Hardin has provided consultancy services to Celgene. H.R. Terebelo has provided consultancy services to Celgene; he has participated in speakers' bureaus for Janssen, Takeda, and Pharmacyclics LLC, an AbbVie Company. L. Wagner has provided consultancy services to EveryFit, Gilead, and Janssen. M. Narang has provided consultancy services and participated in speakers' bureaus for Celgene; he has participated in speakers' bureaus for Janssen. S. Ailawadhi has provided consultancy services to Takeda, Novartis, Celgene, and Amgen; he has received research funding from Pharmacyclics. J.L. Omel has received honoraria from Takeda Oncology and Celgene; he is on the board of directors/advisory committee for Takeda Oncology and Celgene. S. Srinivasan, M. He, B. Ung, A. Kitali, E.D. Flick, and A. Agarwal are employed by Celgene. R. Abonour is a member of steering committees for Celgene and Takeda; he has received research funding from Celgene and Takeda; he has also received research funding from Prothena.The authors thank the patients and their families, nurses, study personnel, and investigators who participated in the Connect MM Registry. This study was funded by Celgene Corporation, which had a role in the study design, collection, analysis and interpretation of data, provided medical writing support, and was involved in the decision to submit the article for publication. Maryann Obiorah provided drafts and editorial assistance to the authors during the preparation of this manuscript, supported by funding from Celgene Corporation. All authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of the article; revised the manuscript critically for important intellectual content; approved the final version to be published; and agreed to be accountable for all aspects of the article.",

year = "2020",

month = may,

doi = "10.1016/j.clml.2019.10.002",

language = "English",

volume = "20",

pages = "272--276",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM)

T2 - Results From The Connect MM Registry

AU - CONNECT MM Registry Investigators

AU - Jagannath, Sundar

AU - Rifkin, Robert M.

AU - Gasparetto, Cristina J.

AU - Toomey, Kathleen

AU - Durie, Brian G.M.

AU - Hardin, James W.

AU - Terebelo, Howard R.

AU - Wagner, Lynne

AU - Narang, Mohit

AU - Ailawadhi, Sikander

AU - Omel, James L.

AU - Srinivasan, Shankar

AU - He, Mia

AU - Ung, Brian

AU - Kitali, Amani

AU - Flick, E. Dawn

AU - Agarwal, Amit

AU - Abonour, Rafat

N1 - Funding Information: The authors thank the patients and their families, nurses, study personnel, and investigators who participated in the Connect MM Registry. This study was funded by Celgene Corporation , which had a role in the study design, collection, analysis and interpretation of data, provided medical writing support, and was involved in the decision to submit the article for publication. Maryann Obiorah provided drafts and editorial assistance to the authors during the preparation of this manuscript, supported by funding from Celgene Corporation . All authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of the article; revised the manuscript critically for important intellectual content; approved the final version to be published; and agreed to be accountable for all aspects of the article. Funding Information: S. Jagannath has provided consultancy services to Celgene, Bristol-Myers Squibb, Novartis, and Merck; he has participated in speakers' bureaus for MMRF and Medicom. R.M. Rifkin has provided consultancy services to Amgen, Boehringer Ingelheim, Celgene, EMD Serono, Sandoz, and Takeda; he owns stock in McKesson. C.J. Gasparetto has received honoraria from Janssen, Bristol-Myers Squibb, Celgene, and Takeda and has provided consultancy services to Janssen, Bristol-Myers Squibb, and Celgene; she has received travel reimbursement from Janssen, Bristol-Myers Squibb, and Celgene, and has received research funding from Celgene. K. Toomey has provided consultancy services to Celgene, has participated in speakers' bureaus for Myriad Genetics, and has received travel reimbursement from Dava Oncology. B.G.M. Durie has provided consultancy services to Takeda and Janssen. J.W. Hardin has provided consultancy services to Celgene. H.R. Terebelo has provided consultancy services to Celgene; he has participated in speakers' bureaus for Janssen, Takeda, and Pharmacyclics LLC, an AbbVie Company. L. Wagner has provided consultancy services to EveryFit, Gilead, and Janssen. M. Narang has provided consultancy services and participated in speakers' bureaus for Celgene; he has participated in speakers' bureaus for Janssen. S. Ailawadhi has provided consultancy services to Takeda, Novartis, Celgene, and Amgen; he has received research funding from Pharmacyclics. J.L. Omel has received honoraria from Takeda Oncology and Celgene; he is on the board of directors/advisory committee for Takeda Oncology and Celgene. S. Srinivasan, M. He, B. Ung, A. Kitali, E.D. Flick, and A. Agarwal are employed by Celgene. R. Abonour is a member of steering committees for Celgene and Takeda; he has received research funding from Celgene and Takeda; he has also received research funding from Prothena.The authors thank the patients and their families, nurses, study personnel, and investigators who participated in the Connect MM Registry. This study was funded by Celgene Corporation, which had a role in the study design, collection, analysis and interpretation of data, provided medical writing support, and was involved in the decision to submit the article for publication. Maryann Obiorah provided drafts and editorial assistance to the authors during the preparation of this manuscript, supported by funding from Celgene Corporation. All authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of the article; revised the manuscript critically for important intellectual content; approved the final version to be published; and agreed to be accountable for all aspects of the article.

PY - 2020/5

Y1 - 2020/5

KW - Community

KW - Real-world

KW - Sankey

KW - Therapies

KW - Transitions

UR - http://www.scopus.com/inward/record.url?scp=85081339846&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.10.002

DO - 10.1016/j.clml.2019.10.002

M3 - Comment/debate

C2 - 32144027

AN - SCOPUS:85081339846

SN - 2152-2650

VL - 20

SP - 272

EP - 276

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 5

ER -